The Skin Condition Nobody Could Treat Just Got a New Challenger

TYK2 inhibitors are more like a dimmer switch for one specific circuit. They target the pathway behind IL-23, IL-12, and type I interferon signaling (key drivers of autoimmune skin disease) while leaving JAK1, JAK2, and JAK3 alone. Bristol-Myers Squibb proved this concept when its TYK2 inhibitor deucravacitinib (Sotyktu) won psoriasis approval in 2022 without the dreaded JAK class boxed warning.

Soficitinib claims roughly 400-fold selectivity for TYK2 over JAK2. That kind of precision is exactly what dermatologists want for a chronic condition like vitiligo, where patients may need years of treatment and the last thing anyone wants is a scary safety label.

A Crowded Race With Very Few Finishers

InnoCare isn't alone in chasing this opportunity, but the field is thinner than you might expect.

Deucravacitinib is being evaluated in a Phase 2/3 investigator-sponsored vitiligo trial, combining the pill with narrowband UVB phototherapy. It's the most established global TYK2 program in the indication, backed by BMS's first-mover status in psoriasis.

Takeda entered the race in August 2025 with zasocitinib (TAK-279), its own highly selective TYK2 inhibitor, in a Phase 2 vitiligo trial. That study is still recruiting and won't produce topline data until participants complete a full year of dosing. No readouts yet.

AbbVie is testing upadacitinib (Rinvoq), a JAK1 inhibitor, in a Phase III vitiligo trial. It's further along in development stage, but it carries the JAK class boxed warning, which could be a real liability in a chronic skin condition that isn't life-threatening.

Then there's Novartis with GIA632 in a Phase IIb dose-ranging study, plus a handful of earlier-stage Chinese programs.

The scorecard so far: no one has produced a successful Phase III systemic result in vitiligo. The first company to do so could own the conversation.

InnoCare's Head Start (and Its Hurdles)

With positive Phase II data in hand, InnoCare now has a slight edge over Takeda's zasocitinib, at least in terms of clinical readouts. The trial was designed as an adaptive Phase II/III study, meaning the Phase III portion rolls forward under the same protocol. That's efficient; no need to start from scratch.

But the Phase III bar is meaningfully higher. The new primary endpoint is F-VASI75 at Week 52: at least 75% facial repigmentation after a full year of treatment. Going from "statistically significant improvement" at 24 weeks to "most of the pigment came back" at 52 weeks is a big leap. Plenty of autoimmune drugs look great at the midpoint and disappoint over the long haul.

InnoCare also faces a strategic question that's as important as the science: geography. The company's clinical footprint is strongest in China, and it's unclear whether soficitinib will pursue FDA or EMA filings independently, or through a licensing partner. BMS and Takeda have built-in global infrastructure. InnoCare doesn't, at least not yet.

The Bigger Picture for Vitiligo Patients

Step back and the trend is encouraging. Five years ago, vitiligo was essentially an orphan in dermatology, a condition millions of people live with but that the pharmaceutical industry barely touched. Now you've got an approved topical (Opzelura), multiple oral TYK2 inhibitors in mid-to-late-stage development, JAK1 programs in Phase III, and a genuine scientific rationale for why these drugs should work.

The unmet need is still enormous. Surveys of vitiligo patients consistently highlight two priorities: emotional well-being from visible repigmentation and access to systemic treatments that can address widespread disease. About 15% of surveyed patients flagged each of these as important but completely unsatisfied by current options.

An effective oral pill that restores pigment with a clean safety profile would be transformative, not just clinically, but commercially. The first company to deliver one could define the category.

What to Watch Next

InnoCare says detailed efficacy and safety data will be presented at an upcoming scientific congress. That's where we'll learn about secondary endpoints, subgroup analyses, and the durability curve that will help predict whether the Phase III bet pays off.

In the meantime, the TYK2 vitiligo race has its first real data point. It's early, but for a disease that went decades without a single approved medicine, early is exactly where momentum starts.

The Drug That Works But Can't Get Made

The FDA just rejected a liver cancer drug for the third consecutive time, and the reason has nothing to do with whether the drug actually works. Hengrui and Elevar's manufacturing woes are becoming a cautionary tale for every biotech relying on overseas factories.